1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Vfend (Voriconazole) Powder For Oral Suspension

Trade Name: Vfend; SPIONIC; Voriconazole Pfizer

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antifungal agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Carcinogenicity: Category 2
Specific target organ systemic toxicity (repeated exposure): Category 2

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

Label Elements

Signal Word: Danger

Hazard Statements:
H360D - May damage the unborn child
H350 - May cause cancer
H373 - May cause damage to organs through prolonged or repeated exposure May form combustible dust concentrations in air

Precautionary Statements:
P202 - Do not handle until all safety precautions have been read and understood
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
SAFETY DATA SHEET

Material Name: Vfend (Voriconazole) Powder For Oral Suspension
Revision date: 22-Mar-2018

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Hazardous Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voriconazole</td>
<td>137234-62-9</td>
<td>Not Listed</td>
<td>Acute Tox.3 (H301) Carc. 2 (H351) Rep. 1B (H360D) STOT RE 2 (H373) Aquatic Acute 3 (H402)</td>
<td>6.67</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>77-92-9</td>
<td>201-069-1</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Silicon dioxide, colloidal NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>236-675-5</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium citrate, dihydrate</td>
<td>6132-04-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>532-32-1</td>
<td>208-534-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Xanthan gum</td>
<td>11138-66-2</td>
<td>234-394-2</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Natural orange flavor</td>
<td>NOT ASSIGNED</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

**Most Important Symptoms and Effects, Both Acute and Delayed**

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

**Indication of the Immediate Medical Attention and Special Treatment Needed**

**Notes to Physician:** None

---

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

**Special Hazards Arising from the Substance or Mixture**

**Hazardous Combustion Products:** Carbon monoxide, carbon dioxide, nitrogen oxides and fluorine-containing compounds

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Advice for Fire-Fighters**

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

---

### 6. ACCIDENTAL RELEASE MEASURES

**Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

**Methods and Material for Containment and Cleaning Up**

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

---

### 7. HANDLING AND STORAGE

**Precautions for Safe Handling**

Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
## Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

**Voriconazole**

- **Pfizer OEL TWA-8 Hr:** 100µg/m³

**Sucrose**

- **ACGIH Threshold Limit Value (TWA):** 10 mg/m³
- **Australia TWA:** 10 mg/m³
- **Belgium OEL - TWA:** 10 mg/m³
- **Bulgaria OEL - TWA:** 10.0 mg/m³
- **Estonia OEL - TWA:** 10 mg/m³
- **France OEL - TWA:** 10 mg/m³
- **Ireland OEL - TWAs:** 10 mg/m³
- **Latvia OEL - TWA:** 5 mg/m³
- **Lithuania OEL - TWA:** 10 mg/m³
- **OSHA - Final PELs - TWAs:** 15 mg/m³
- **Portugal OEL - TWA:** 10 mg/m³
- **Slovakia OEL - TWA:** 6 mg/m³
- **Spain OEL - TWA:** 10 mg/m³

**Silicon dioxide, colloidal NF**

- **Australia TWA:** 2 mg/m³
- **Austria OEL - MAKs:** 4 mg/m³
- **Czech Republic OEL - TWA:** 0.1 mg/m³
- **OSHA - Final PELs - Table Z-3 Mineral D:** Listed
- **Latvia OEL - TWA:** 1 mg/m³
- **Slovakia OEL - TWA:** 4.0 mg/m³
- **Slovenia OEL - TWA:** 0.3 mg/m³
- **Switzerland OEL -TWAs:** 4 mg/m³

**Titanium dioxide**

- **ACGIH Threshold Limit Value (TWA):** 10 mg/m³
- **Australia TWA:** 10 mg/m³
- **Austria OEL - MAKs:** 5 mg/m³
- **Belgium OEL - TWA:** 10 mg/m³
- **Bulgaria OEL - TWA:** 10.0 mg/m³
- **Denmark OEL - TWA:** 6 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:
Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:
Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:
Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Odor: No data available.
Molecular Formula: Mixture
Solvent Solubility: No data available
Water Solubility: No data available
pH: 3.5-4.5 (reconstituted)
Melting/Freezing Point (°C): No data available
9. PHYSICAL AND CHEMICAL PROPERTIES

Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)

Voriconazole
Measured 7 Log P 1.75
Silicon dioxide, colloidal NF
No data available
Titanium dioxide
No data available
Xanthan gum
No data available
Sodium citrate, dihydrate
No data available
Sodium benzoate
No data available
Citric acid, anhydrous
No data available
Natural orange flavor
No data available
Sucrose
No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available
Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
11. TOXICOLOGICAL INFORMATION

Short Term: Harmful if swallowed. May produce slight eye irritation. (based on components). Accidental ingestion may cause effects similar to those seen in clinical use.

Long Term: Adverse reproductive effects seen in repeat-dose animal studies are consistent with the pharmacologic action of this drug and are expected to be relevant to humans. Animal studies indicate that this material may cause adverse effects on the liver, the developing fetus.

Known Clinical Effects: The most common adverse effects reported with clinical use of voriconazole include visual disturbances, elevations of liver function tests and skin rash. Voriconazole has been associated with photosensitivity skin reactions especially during long term therapy.

Acute Toxicity: (Species, Route, End Point, Dose)

<table>
<thead>
<tr>
<th>Material</th>
<th>Species</th>
<th>Route</th>
<th>LD50</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voriconazole</td>
<td>Rat/Mouse</td>
<td>Oral</td>
<td>&lt; 300 mg/kg</td>
<td>&lt; 300 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat/Mouse</td>
<td>Oral</td>
<td>LDmin.</td>
<td>&gt; 100 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>IV</td>
<td>LD50</td>
<td>&gt; 100 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Dermal</td>
<td>LD50</td>
<td>&gt; 2000 mg/kg</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>&gt; 7500 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Subcutaneous</td>
<td>LD50</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td>Xanthan gum</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>&gt; 5000 mg/kg</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>4,070 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Oral</td>
<td>LD50</td>
<td>1600 mg/kg</td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>3000 mg/kg</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Rat</td>
<td>Oral</td>
<td>LD50</td>
<td>29.7 g/kg</td>
</tr>
</tbody>
</table>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

<table>
<thead>
<tr>
<th>Material</th>
<th>Study Type</th>
<th>Species</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voriconazole</td>
<td>Skin Irritation</td>
<td>Rabbit</td>
<td>Non-irritating</td>
</tr>
<tr>
<td></td>
<td>Skin Sensitization - GPMT</td>
<td>Guinea Pig</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>Eye Irritation</td>
<td>Rabbit</td>
<td>Minimal</td>
</tr>
<tr>
<td>Citric acid, anhydrous</td>
<td>Eye Irritation</td>
<td>Rabbit</td>
<td>Severe</td>
</tr>
<tr>
<td></td>
<td>Skin Irritation</td>
<td>Rabbit</td>
<td>Mild</td>
</tr>
</tbody>
</table>

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
11. TOXICOLOGICAL INFORMATION

Voriconazole

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Month(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>30 mg/kg/day</td>
<td>NOAEL</td>
</tr>
<tr>
<td>6 Month(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>3 mg/kg/day</td>
<td>NOAEL</td>
</tr>
<tr>
<td>12 Month(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>8 mg/kg/day</td>
<td>NOAEL</td>
</tr>
<tr>
<td>6 Month(s)</td>
<td>Rat</td>
<td>Intravenous</td>
<td>10 mg/kg/day</td>
<td>NOAEL</td>
</tr>
<tr>
<td>6 Month(s)</td>
<td>Dog</td>
<td>Oral</td>
<td>6 mg/kg/day</td>
<td>NOAEL</td>
</tr>
</tbody>
</table>

Sodium benzoate

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 Day(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>27370 mg/kg</td>
<td>LOAEL</td>
</tr>
<tr>
<td>10 Day(s)</td>
<td>Mouse</td>
<td>Oral</td>
<td>45 g/kg</td>
<td>LOAEL</td>
</tr>
</tbody>
</table>

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Voriconazole

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reproductive &amp; Fertility</td>
<td>Rat</td>
<td>Oral</td>
<td>3 mg/kg/day</td>
<td>NOAEL</td>
</tr>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Oral</td>
<td>10 mg/kg/day</td>
<td>LOAEL</td>
</tr>
</tbody>
</table>

Sodium benzoate

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo / Fetal Development</td>
<td>Rat</td>
<td>Oral</td>
<td>44 g/kg</td>
<td>LOEL</td>
</tr>
</tbody>
</table>

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Voriconazole

<table>
<thead>
<tr>
<th>Study Type</th>
<th>Cell Type/Organism</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>Bacteria</td>
<td>Negative</td>
</tr>
<tr>
<td>\textit{In Vitro}</td>
<td>Human Lymphocytes</td>
<td>Equivocal</td>
</tr>
<tr>
<td>\textit{In Vivo}</td>
<td>Micronucleus Mouse</td>
<td>Negative</td>
</tr>
<tr>
<td>Sucrose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>\textit{Salmonella}</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Voriconazole

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>Effect(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Year(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>18 mg/kg/day</td>
<td>NOEL</td>
</tr>
<tr>
<td>2 Year(s)</td>
<td>Mouse</td>
<td>Oral</td>
<td>30 mg/kg/day</td>
<td>NOAEL</td>
</tr>
</tbody>
</table>

Carcinogen Status:

See below

Silicon dioxide, colloidal NF

<table>
<thead>
<tr>
<th>Agency</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>IARC</td>
<td>Group 3 (Not Classifiable)</td>
</tr>
<tr>
<td>NTP</td>
<td>Reasonably Anticipated To Be A Human Carcinogen</td>
</tr>
</tbody>
</table>

Titanium dioxide

<table>
<thead>
<tr>
<th>Agency</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>IARC</td>
<td>Group 2B (Possibly Carcinogenic to Humans)</td>
</tr>
</tbody>
</table>
12. ECOLOGICAL INFORMATION

Environmental Overview: In the environment, the active ingredient in this formulation is expected to remain in water or migrate through the soil to groundwater and degrade slowly. Harmful effects to aquatic organisms could occur.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

**Voriconazole**

<table>
<thead>
<tr>
<th>Mycisopsis bahia (Mysid Shrimp)</th>
<th>NPDES</th>
<th>LC50</th>
<th>48 Hours</th>
<th>62 mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red Algae</td>
<td>IC50</td>
<td>73 mg/L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skeletonema costatum (Marine Diatom)</td>
<td>NPDES</td>
<td>IC-50</td>
<td>48 Hours</td>
<td>74.7 mg/L</td>
</tr>
<tr>
<td>Green Algae</td>
<td>OECD</td>
<td>EbC50/72hr (OECD)</td>
<td>EC50</td>
<td>72 Hours</td>
</tr>
<tr>
<td>Oncorhynchus mykiss (Rainbow Trout)</td>
<td>OECD</td>
<td>LC50</td>
<td>96 Hours</td>
<td>110 mg/L</td>
</tr>
</tbody>
</table>

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

**Voriconazole**

|Activated sludge | OECD | EC50 | > 810 mg/L |
|Polytox | MIC | > 100 mg/L |

Chronic Aquatic Toxicity: (Species, Method, Duration, Endpoint, Result, Adverse Endpoint)

**Voriconazole**

|Daphnia magna (Water Flea) | OECD | 21 Day(s) | NOEC | > 1 mg/L |
|Pimephales promelas (Fathead Minnow) | OECD | 32 Day(s) | NOEC | 1.2 mg/L |
|Chironomus riparius (Sediment-Dwelling Midge) | OECD | 28 Day(s) | NOEC | 100 mg/L |

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

**Voriconazole**

|OECD | Activated sludge | Ultimate (CO2 Evolution) | -0.24% After 28 Day(s) | Not Ready |

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

**Voriconazole**

|Measured | 7 | Log P | 1.75 |

Mobility in Soil: No data available
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Voriconazole
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List: Not Listed

Sucrose
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- REACH - Annex IV - Exemptions from the obligations of Register: Present
- EU EINECS/ELINCS List: 200-334-9

Citric acid, anhydrous
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 201-069-1

Silicon dioxide, colloidal NF
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material</th>
<th>CERCLA/SARA 313 Emission reporting</th>
<th>California Proposition 65</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS)</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Titanium dioxide</td>
<td></td>
<td></td>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td>California Proposition 65</td>
<td>Not Listed</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA -</td>
<td></td>
<td>Inventory - United States TSCA - Sect. 8(b)</td>
<td>Present</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Sect. 8(b)</td>
<td></td>
<td>Australia (AICS):</td>
<td>Present</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td>Sodium benzoate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td></td>
<td>Not Listed</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td></td>
<td>Not Listed</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA -</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Sect. 8(b)</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Australia (AICS):</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td>Xanthan gum</td>
<td>CERCLA/SARA 313 Emission reporting</td>
<td>Not Listed</td>
<td></td>
<td>Not Listed</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>California Proposition 65</td>
<td></td>
<td></td>
<td>Not Listed</td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Inventory - United States TSCA -</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Sect. 8(b)</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>Australia (AICS):</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
<tr>
<td></td>
<td>EU EINECS/ELINCS List</td>
<td></td>
<td></td>
<td></td>
<td>EU EINECS/ELINCS List</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Carcinogenicity-Cat.2; H350 - May cause cancer
Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure
Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients.
SAFETY DATA SHEET

Material Name: Vfend (Voriconazole) Powder For Oral Suspension
Revision date: 22-Mar-2018

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection.
Revision date: 22-Mar-2018

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet